<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Montalescot, Gilles</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ARCTIC: Randomized Trial of Bedside Platelet Function Monitoring</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-24</style></pages><abstract><style  face="normal" font="default" size="100%">Responses to oral antiplatelet therapy between patients are variable; thus, bedside assessment has been regarded as an opportunity for individualizing therapy for patients following coronary stent implantation to ensure the optimal platelet inhibition is obtained. The Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation and Interruption Versus Continuation of Double Antiplatelet Therapy [ARCTIC; NCT00827411; Collet JP et al. N Engl J Med 2012] trial evaluated platelet function testing with antiplatelet dose adjustment in suboptimal responders compared with standard of care.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>